9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.PierFranco Conte, Valentina Guarneri, Elisa Picardo et al.|Journal of Clinical Oncology|2017Cited by 36
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratioPierFranco Conte, Roberto D’Amico, Valentina Guarneri et al.|Annals of Oncology|2018Cited by 6
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experienceE.S. Lutrino, Saverio Cinieri, Laura Orlando et al.|Tumori Journal|2019Cited by 6
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients: Results on safety and efficacy—An Italian multicenter experience.Stefania Eufemia Lutrino, Saverio Cinieri, Laura Orlando et al.|Journal of Clinical Oncology|2016Cited by 3
Safety and efficacy of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients. An Italian multicenter experienceE.S. Lutrino, Saverio Cinieri, Laura Orlando et al.|Annals of Oncology|2016Cited by 1